Replication FailureOpen accessMedicine· cited by 36

Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial

John Lowe; David Gillespie; Ali F. Aboklaish; Mandy Lau; Claudia Consoli; Malavika Babu; Mark Goddard; Kerenza Hood · 2024 · The Lancet Respiratory Medicine

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: Systematic reviews have reported conflicting evidence on whether macrolide antibiotics reduce rates of chronic lung disease of prematurity (CLD) in at-risk preterm infants born at less than 30 weeks' gestation, including in those colonised with pulmonary Ureaplasma spp. Since an adequately powered trial has been lacking, we aimed to assess if the macrolide azithromycin improved survival without the development of physiologically defined moderate or severe CLD in preterm infants. METHODS: AZTEC was a multicentre, double-blind, randomised, placebo-controlled trial conducted in 28 ter

Abstract by John Lowe; David Gillespie; Ali F. Aboklaish; Mandy Lau; Claudia Consoli; Malavika Babu; Mark Goddard; Kerenza Hood, The Lancet Respiratory Medicine (2024) — licensed CC BY 4.0.

Read the full paper (open access)